Evaluation of the INDICAID COVID-19 Rapid Antigen Test in Symptomatic Populations and Asymptomatic Community Testing.

  1. As the COVID-19 pandemic progresses, there is an increasing need for rapid, accessible assays for SARS-CoV-2 detection. We present a clinical evaluation and real-world implementation of the INDICAID COVID-19 rapid antigen test (INDICAID rapid test).
  2. A multisite clinical evaluation of the INDICAID rapid test using prospectively collected nasal (bilateral anterior) swab samples from symptomatic subjects was performed. The INDICAID rapid test demonstrated a positive percent agreement (PPA) and negative percent agreement (NPA) of 85.3% (95% confidence interval [95% CI], 75.6% to 91.6%) and 94.9% (95% CI, 91.6% to 96.9%), respectively, compared to laboratory-based reverse transcriptase PCR (RT-PCR) using nasal specimens.
  3. The INDICAID rapid test was then implemented at COVID-19 outbreak screening centers in Hong Kong as part of a testing algorithm (termed “dual-track”) to screen asymptomatic individuals for prioritization for confirmatory RT-PCR testing.
  4. In one approach, preliminary positive INDICAID rapid test results triggered expedited processing for laboratory-based RT-PCR, reducing the average time to confirmatory result from 10.85 h to 7.0 h. In a second approach, preliminary positive results triggered subsequent testing with an onsite rapid RT-PCR, reducing the average time to confirmatory result to 0.84 h. In 22,994 asymptomatic patients, the INDICAID rapid test demonstrated a PPA of 84.2% (95% CI, 69.6% to 92.6%) and an NPA of 99.9% (95% CI, 99.9% to 100%) compared to laboratory-based RT-PCR using combined nasal/oropharyngeal specimens.
  5. The INDICAID rapid test has excellent performance compared to laboratory-based RT-PCR testing and, when used in tandem with RT-PCR, reduces the time to confirmatory positive result. IMPORTANCE Laboratory-based RT-PCR, the current gold standard for COVID-19 testing, can require a turnaround time of 24 to 48 h from sample collection to result.
  6. The delayed time to result limits the effectiveness of centralized RT-PCR testing to reduce transmission and stem potential outbreaks. To address this, we conducted a thorough evaluation of the INDICAID COVID-19 rapid antigen test, a 20-minute rapid antigen test, in both symptomatic and asymptomatic populations.
  7. The INDICAID rapid test demonstrated high sensitivity and specificity with RT-PCR as the comparator method.
  8. A dual-track testing algorithm was also evaluated utilizing the INDICAID rapid test to screen for preliminary positive patients, whose samples were then prioritized for RT-PCR testing. The dual-track method INDICAID COVID test demonstrated significant improvements in expediting the reporting of positive RT-PCR test results compared to standard RT-PCR testing without prioritization, offering an improved strategy for community testing and controlling SARS-CoV-2 outbreaks.

Direct Detection of Feline Coronavirus by Three Rapid Antigen Immunochromatographic Tests and by Real-Time PCR in Cat Shelters

  1. The aim of this study was the direct detection of feline coronavirus by real-time PCR and by three different rapid immunochromatographic (RIM) tests detecting antigens in faecal samples of shelter cats. Based on sensitivity and specificity calculated for each of the RIM tests, the utility of RIM tests was compared. Seventy faecal samples originating from shelter cats housed in quarantine were examined.
  2. Out of 70 samples analyzed by real-time PCR, 44 (62.9%) were positive. Significantly more cats (p < 0.05) tested positive than negative. Neither age nor sex of the cats played a significant role (p > 0.05) in the shedding status of the virus.
  3. The sensitivity of the RIM tests was found to be at low (<35%; RIM tests A and C) to satisfactory level (>50%, RIM test B). The number of virus particles determined by real-time RT-PCR analysis did not significantly correlate with the results detected by any of the RIM tests (p > 0.05). The results of this study indicate that the use of rapid antigen RIM tests in routine screening of FCoV shedding status in shelter cats is limited due to the occurrence of a high number of false negative results.

Antigen Test Positivity After COVID-19 Isolation – Yukon-Kuskokwim Delta Region, Alaska, January-February 2022.

  • Isolation is recommended during acute infection with SARS-CoV-2, the virus that causes COVID-19, but the duration of infectiousness varies among individual persons. Rapid antigen test results have been correlated with detection of viable virus (1-3) and might inform isolation guidance, but data are limited for the recently emerged SARS-CoV-2 B.1.1.529 (Omicron) variant.
  • On January 5, 2022, the Yukon-Kuskokwim Health Corporation (YKHC) recommended that persons with SARS-CoV-2 infection isolate for 10 days after symptom onset (or, for asymptomatic persons, 10 days after a positive nucleic acid amplification or antigen test result).
  • However, isolation could end after 5-9 days if symptoms were resolving or absent, fever was absent for ≥24 hours without fever-reducing medications, and an Abbott BinaxNOW COVID-19 Ag (BinaxNOW) rapid antigen test result was negative.
  • Antigen test results and associated individual characteristics were analyzed among 3,502 infections reported to YKHC during January 1-February 9, 2022. After 5-9 days, 396 of 729 persons evaluated (54.3%) had a positive antigen test result, with a declining percentage positive over time.
  • In a multivariable model, a positive antigen test result was more likely after 5 days compared with 9 days (adjusted odds ratio [aOR] = 6.39) or after symptomatic infection (aOR = 9.63), and less likely after previous infection (aOR = 0.30), receipt of a primary COVID-19 vaccination series (aOR = 0.60), or after both previous infection and receipt of a primary COVID-19 vaccination series (aOR = 0.17).
INDICAID Rapid Antigen Test
INDICAID Rapid Antigen Test
  • Antigen tests might be a useful tool to guide recommendations for isolation after SARS-CoV-2 infection. During the 10 days after infection, persons might be infectious to others and are recommended to wear a well-fitting mask when around others, even if ending isolation after 5 days.

Impaired detection of omicron by SARS-CoV-2 rapid antigen tests.

  • Since autumn 2020, rapid antigen tests (RATs) have been implemented in several countries as an important pillar of the national testing strategy to rapidly screen for infections on site during the SARS-CoV-2 pandemic. The current surge in infection rates around the globe is driven by the variant of concern (VoC) omicron (B.1.1.529).
  • Here, we evaluated the performance of nine SARS-CoV-2 RATs in a single-centre laboratory study. We examined a total of 115 SARS-CoV-2 PCR-negative and 166 SARS-CoV-2 PCR-positive respiratory swab samples (101 omicron, 65 delta (B.1.617.2)) collected from October 2021 until January 2022 as well as cell culture-expanded clinical isolates of both VoCs.
  • In an assessment of the analytical sensitivity in clinical specimen, the 50% limit of detection (LoD50) ranged from 1.77 × 106 to 7.03 × 107 RNA copies subjected to the RAT for omicron compared to 1.32 × 105 to 2.05 × 106 for delta. To score positive in these point-of-care tests, up to 10-fold (LoD50) or 101-fold (LoD95) higher virus loads were required for omicron- compared to delta-containing samples.
  • The rates of true positive test results for omicron samples in the highest virus load category (Ct values < 25) ranged between 31.4 and 77.8%, while they dropped to 0-8.3% for samples with intermediate Ct values (25-30).

Hepatitis B Surface Antigen (HBsAg) ELISA kit, Qualitative, 96 tests,

4105 Alpha Diagnostics 1 Kit

Human Anti-Smith antigen (Sm) IgG ELISA kit, 96 tests, Quantitative

3300-100-SMG Alpha Diagnostics 1 kit

Human Anti-Smith antigen/RNP (Sm/RNP) IgG ELISA kit, 96 tests, Quantitative

3300-110-SRG Alpha Diagnostics 1 kit

Clostridium difficile Toxin/Toxoid A antigen ELISA kit, 96 tests, Quantitative

CDTA-010-96 Alpha Diagnostics 1 Kit

Anthrax Protective Antigen 83 (PA83) Protein ELISA kit, 96 tests, Quantitative Kit

800-100-P83 Alpha Diagnostics 1 Kit

Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA Kit, 48 tests, Quantitative

AE-320800-48 Alpha Diagnostics 1 kit

Zaire Ebola Virus Glycoprotein (EBOV GP antigen) ELISA Kit, 96 tests, Quantitative

AE-320800-96 Alpha Diagnostics 1 kit

West Nile Virus NS1 Protein (WNV-NS1) antigen ELISA kit, 96 tests, Quantitative

910-290-NS1 Alpha Diagnostics 1 Kit

Horse Anti-Anthrax Protective Antigen 83 (PA83) IgG ELISA kit, 96 tests, quantitative

900-145-83G Alpha Diagnostics 1 Kit

Human Anti-Anthrax Protective Antigen 83 (PA83) IgG ELISA kit, 96 tests, quantitative

900-165-83G Alpha Diagnostics 1 Kit

Sheep Anti-Anthrax Protective Antigen 83 (PA83) IgG ELISA kit, 96 tests, quantitative

900-170-83G Alpha Diagnostics 1 Kit

Camel Anti-Anthrax Protective Antigen 83 (PA83) IgG ELISA kit, 96 tests, quantitative

900-180-83G Alpha Diagnostics 1 Kit

Recombivirus PRRSV NP Type 1 antigen coated plates for ELISA (5x96 tests), Quantitative

RV-400106-CP5 Alpha Diagnostics 1 pk

Recombivirus PRRSV NP Type 2 antigen coated plates for ELISA (5x96 tests), Quantitative

RV-400116-CP5 Alpha Diagnostics 1 kit

Mouse Anti-Anthrax Protective Antigen 83 (PA83) Ig?s ELISA kit, 96 tests, Quantitative

900-100-83T Alpha Diagnostics 1 Kit

Rabbit Anti-Anthrax Protective Antigen 83 (PA83) Ig?s ELISA kit, 96 tests, quantitative

900-120-83T Alpha Diagnostics 1 Kit

Monkey Anti-Anthrax Protective Antigen 83 (PA83) Ig?s ELISA kit, 96 tests, quantitative

900-150-83T Alpha Diagnostics 1 Kit

Human Anti-Anthrax Protective Antigen 83 (PA83) Ig?s ELISA kit, 96 tests, quantitative

900-160-83T Alpha Diagnostics 1 Kit

Recombivirus PRRSV NSP Type 1 antigen coated plates for ELISA (5x96 tests), Quantitative

RV-400136-CP5 Alpha Diagnostics 1 pk

Recombivirus PRRSV NSP Type 2 antigen coated plates for ELISA (5x96 tests), Quantitative

RV-400146-CP5 Alpha Diagnostics 1 kit

Rat Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgG ELISA kit, 96 tests, quantitative

4270 Alpha Diagnostics 1 Kit

Rat Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative

4270-30-IGA Alpha Diagnostics 1 Kit

Human Anti-Proliferating Cell Nuclear Antigen (PCNA) IgG ELISA kit, 96 tests, Quantitative

5025 Alpha Diagnostics 1 Kit

Monkey Anti-Proliferating Cell Nuclear Antigen (PCNA) IgG ELISA kit, 96 tests, Quantitative

5030 Alpha Diagnostics 1 Kit

G. pig Anti-Anthrax Protective Antigen 83 (PA83) Ig?s ELISA kit, 96 tests, quantitative

900-140-83T Alpha Diagnostics 1 Kit

Human Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative

4200-30-IGA Alpha Diagnostics 1 Kit

Mouse Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgG ELISA kit, 96 tests, quantitative

4210 Alpha Diagnostics 1 Kit

Mouse Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative

4210-30-IGA Alpha Diagnostics 1 Kit

Human Anti-Hepatitis B Surface Antigen IgG (anti-HBsAg) ELISA kit, Quantitative, 96 tests

4220-AHB Alpha Diagnostics 1 Kit

Mouse CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4/CD152) ELISA Kit, 96 tests, quantitative

210-220-CA4 Alpha Diagnostics 1 Kit

Human CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4/CD152) ELISA Kit, 96 tests, quantitative

210-230-CA4 Alpha Diagnostics 1 Kit

Recombivirus PRRSV NP Type 1+2 antigen coated plates for ELISA (5x96 tests), Quantitative

RV-400126-CP5 Alpha Diagnostics 1 pk

Recombivirus Foot and mouth disease virus 3AB antigen coated plates for ELISA (5x96 tests)

RV-400771-CP5 Alpha Diagnostics 1 pk

Recombivirus 1+2+3 E2 Protein antigen coated plates for ELISA (5x96 tests), Quantitative

RV-500181-CP5 Alpha Diagnostics 1 pk

Rabbit Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgG ELISA kit, 96 tests, quantitative

4240 Alpha Diagnostics 1 Kit

Monkey Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgA ELISA kit, 96 tests, quantitative

4250-30-IGA Alpha Diagnostics 1 Kit

G. pig Anti-Hepatitis B Surface Antigen (anti-HBsAg) IgG ELISA kit, 96 tests, quantitative

4260 Alpha Diagnostics 1 Kit

Recombivirus PRRSV NSP Type 1+2 antigen coated plates for ELISA (5x96 tests), Quantitative

RV-400156-CP5 Alpha Diagnostics 1 pk

Mouse Anti-Anthrax Protective Antigen 83 (PA83) IgG-specific) ELISA kit, 96 tests, quantitative

900-105-83G Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) early antigen (EA) IgA ELISA Kit, 96 tests, quantitative

510-215-HEA Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) early antigen (EA) IgG ELISA Kit, 96 tests, quantitative

510-220-HEG Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) early antigen (EA) IgM ELISA Kit, 96 tests, quantitative

510-225-HEM Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) Early antigen (D) IgG ELISA Kit, 96 tests, quantitative

510-245-EDG Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) Early antigen (D) IgM ELISA Kit, 96 tests, quantitative

510-250-EDM Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) Early antigen (D) IgA ELISA Kit, 96 tests, quantitative

510-255-EDA Alpha Diagnostics 1 Kit

Recombivirus BVDV 1 Erns 1 Erns (BVDV1-Erns) Protein antigen coated plates for ELISA (5x96 tests)

RV-500281-CP5 Alpha Diagnostics 1 pk

Human Anti-Meningitis B Neisserial Heparin Binding Antigen (NHBA) IgG ELISA kit, 96 tests, quantitative

600-920-HHG Alpha Diagnostics 1 kit

Mouse Anti-Meningitis B Neisserial Heparin Binding Antigen (NHBA) IgG ELISA kit, 96 tests, quantitative

600-925-MHG Alpha Diagnostics 1 kit

Rabbit Anti-Meningitis B Neisserial Heparin Binding Antigen (NHBA) IgG ELISA kit, 96 tests, quantitative

600-970-RHG Alpha Diagnostics 1 kit

Humanized/Human Anti-Anthrax Protective Antigen 83 (PA83) IgG activity ELISA kit, 96 tests, quantitative

900-155-HPA Alpha Diagnostics 1 Kit

Urinary Indican Test Kit

I1000N BioAssay Systems 20

UVC Indicator Cards, pack of 25

B1450-IC Benchmark Scientific 1 each

Human Anti-Hepatitis B Surface Antigen Pres-S2 (HB-Pre-S2) IgM ELISA kit, 96 tests, quantitative

4405 Alpha Diagnostics 1 Kit

Human Anti-Hepatitis B Surface Antigen Pres-S1 (HB-Pre-S1) IgM ELISA kit, 96 tests, quantitative

4305 Alpha Diagnostics 1 Kit

Mouse Anti-Hepatitis B Surface Antigen Pres-S1 (HB-Pre-S1) IgG ELISA kit, 96 tests, quantitative

4310 Alpha Diagnostics 1 Kit

Mouse Anti-Hepatitis B Surface Antigen Pres-S1 (HB-Pre-S1) IgM ELISA kit, 96 tests, quantitative

4315 Alpha Diagnostics 1 Kit

Rat Rena-strip Kit, 25 tests

R-RENA-LF-025 BioAssayWorks 25 tests

Monkey Anti-Hepatitis B Surface Antigen Pres-S1 (HB-Pre-S1) IgM ELISA kit, 96 tests, quantitative

4355 Alpha Diagnostics 1 Kit

Monkey Anti-Hepatitis B Surface Antigen Pres-S2 (HB-Pre-S2) IgG ELISA kit, 96 tests, quantitative

4450 Alpha Diagnostics 1 Kit

Monkey Anti-Hepatitis B Surface Antigen Pres-S2 (HB-Pre-S2) IgM ELISA kit, 96 tests, quantitative

4455 Alpha Diagnostics 1 Kit

Rabbit Anti-Hepatitis B Surface Antigen Pres-S1 (HB-Pre-S1) IgG ELISA kit, 96 tests, quantitative

4340 Alpha Diagnostics 1 Kit

Monkey Anti-Hepatitis B Surface Antigen Pres-S1 (HB-Pre-S1) IgG ELISA kit, 96 tests, quantitative

4350 Alpha Diagnostics 1 Kit

Human Anti-H. Influenzae B (Hib) polyribosyl phosphate (PRP) antigen (vaccine) ELISA Kit, 96 tests, Quantitative

980-HIB-AG1 Alpha Diagnostics 1 Kit

Human Rena-strip Kit, 25 tests

H-RENA-LF-025 BioAssayWorks 25 tests

Human Anti-Epstein Barr Virus (EBV/HHV-4) virus capsid antigen (VCA) IgA ELISA Kit, 96 tests, quantitative

510-230-HEA Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) virus capsid antigen (VCA) IgG ELISA Kit, 96 tests, quantitative

510-235-HEG Alpha Diagnostics 1 Kit

Human Anti-Epstein Barr Virus (EBV/HHV-4) virus capsid antigen (VCA) IgM ELISA Kit, 96 tests, quantitative

510-240-HEM Alpha Diagnostics 1 Kit

Free Chlorine Reagent set (25 tests)

HI-701-25 Scientific Laboratory Supplies PK25

Total Chlorine Reagent set (25 tests)

HI-711-25 Scientific Laboratory Supplies PK25

Human Anti-Epstein Barr Virus (EBV/HHV-4) Nuclear Antigen 1 (EBNA-1) IgA ELISA Kit, 96 tests, quantitative

510-200-HEA Alpha Diagnostics 1 Kit
Of note, testing of expanded virus stocks suggested a comparable RAT sensitivity of both VoCs, questioning the predictive value of this type of in vitro-studies for clinical performance. Given their importance for national test strategies in the current omicron wave, awareness must be increased for the reduced detection rate of omicron infections by RATs and a short list of suitable RATs that fulfill the minimal requirements of performance should be rapidly disclosed.

Leave a Comment

Your email address will not be published.

Scroll to Top